|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net Income Loss | |||||
| Adjustments to reconcile net profit (loss) to cash provided by (used in) operating activities | |||||
| Depreciation | |||||
| Amortization of intangible assets | |||||
| Debt issuance cost amortization | |||||
| Depreciation and amortization | |||||
| Original issue discount, debt premium and debt issuance cost amortization | |||||
| Reorganization items | |||||
| Interest on BR Exar AR Facility | |||||
| Debt modification and extinguishment loss (gain), net | |||||
| Provision for credit losses | |||||
| Deferred income tax provision | |||||
| Equity-based compensation expense | |||||
| Unrealized foreign currency (gain) loss | |||||
| Change in deferred income taxes | |||||
| Loss (gain) on sale of assets | |||||
| Fair value adjustment for private warrants liability | |||||
| Paid-in-kind interest | |||||
| Change in operating assets and liabilities, net of effect from acquisitions | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable | |||||
| Related party payables | |||||
| Accrued expenses and other liabilities | |||||
| Deferred revenue | |||||
| Customer deposits | |||||
| Accounts payable and accrued liabilities | |||||
| Related party receivables (payables) | |||||
| Additions to outsourced contract costs | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows from investing activities | |||||
| Net cash received from acquisition (Refer Note 5) | |||||
| Purchase of property, plant and equipment | |||||
| Cash paid for costs of fulfilling a contract | |||||
| Additions to internally developed software | |||||
| Proceeds from sale of assets | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities | |||||
| Borrowings under secured borrowing facility | |||||
| Cash paid for debt issuance costs | |||||
| Principal payments on finance lease obligations | |||||
| Proceeds from Business Combination, net of transaction expenses | |||||
| Borrowings from other loans | |||||
| Proceeds from Issuance of July 2030 Notes | |||||
| Proceeds from Facility | |||||
| Revolvers | |||||
| ABL Facility maturing July 29, 2028 | |||||
| BR Exar AR Facility | |||||
| Proceeds from Super Senior Term Loan | |||||
| Repayments of Facility | |||||
| Secured Term Loan A | |||||
| Secured Term Loan B | |||||
| ABL Facility maturing July 29, 2028 | |||||
| BR Exar AR Facility | |||||
| Principal payments on long-term obligations | |||||
| Repayment of Second Lien Note | |||||
| Borrowings under 2024 Term Loan Facility | |||||
| Secured Term Loan A | |||||
| Secured Term Loan B | |||||
| 2024 Revolving Credit Facility | |||||
| Proceeds from DIP New Money Loans | |||||
| Principal repayments on senior secured term loans and other loans | |||||
| Net cash provided by (used in) financing activities | |||||
| Effect of exchange rates on cash, restricted cash and cash equivalents | |||||
| Net increase (decrease) in cash, restricted cash and cash equivalents | |||||
| Cash and equivalents, beginning of period, including cash from discontinued operations | |||||
| Cash and equivalents, end of period, including cash from discontinued operations | |||||
| Cash, restricted cash and cash equivalents | |||||
| Beginning of period | |||||
| End of period | |||||
| Supplemental cash flow data: | |||||
| Income tax payments, net of refunds received | |||||
| Interest paid | |||||
| Cash paid for reorganization items | |||||
| Noncash investing and financing activities: | |||||
| Assets acquired through right-of-use arrangements | |||||
| Waiver and consent fee payable added to outstanding balance of Senior Secured Term Loan | |||||
| Promissory note issued for assets acquisition | |||||
| Common stock issued for the Business Combination | |||||
| Common stock issued to settle liabilities subject to compromise | |||||
| Issuance of July 2030 Notes for settlement of the DIP Facility | |||||
| Conversion of DIP Facility into Super Senior Term Loan | |||||
| Accrued capital expenditures | |||||
Loading...